相关实验视频
Updated: May 31, 2025

08:02
A Mouse Ear Model for Allergic Contact Dermatitis Evaluation
Published on: March 24, 2023
3.3K
Aspergillus oryzae发酵的Plumula Nelumbinis通过AKT/mTOR和Jun途径对抗亚托皮炎
Fengfeng Chen1, Jing Liu1, Xinwei Yu1
1Key Laboratory of Synthetic and Biological Colloids, Ministry of Education, School of Chemical and Material Engineering, Jiangnan University, Wuxi 214122, China.
Pharmaceuticals (Basel, Switzerland)
|January 25, 2025
概括
发酵Plumula Nelumbinis (FPN) 通过向关键路径,显示出对抗亚托皮炎 (AD) 的抗炎作用. 发酵增强了Plumula Nelumbinis类化合物的活性,为新的AD药物开发提供了潜力.
科学领域:
- 药理学 药理学是指药理学的学科.
- 自然产品 化学 化学
- 皮肤病学 皮肤病学
背景情况:
- 亚托皮炎 (AD) 是一种普遍存在的慢性炎症性皮肤疾病.
- 来自Plumula Nelumbinis的类化合物具有抗炎性质.
- 自然化合物的发酵可以增强它们的治疗潜力,但FPN对AD的疗效在很大程度上是未知的.
研究的目的:
- 研究发酵Plumula Nelumbinis (FPN) 在治疗阿托皮性皮炎 (AD) 中的治疗疗效和潜在机制.
- 在AD治疗中识别FPN的关键分子标.
- 为了评估阿斯伯吉勒斯菌发酵对Plumula Nelumbinis的抗炎活性的影响.
主要方法:
- 网络药理学被用来预测AD的FPN的潜在治疗点.
- 聚合酶连锁反应 (PCR) 和西部涂抹 (WB) 用于验证体外治疗效果.
- 斑马鱼模型被用来评估FPN缓解炎症的能力.
主要成果:
- 网络药理学确定了mTOR和Jun作为AD的关键目标.
- 在实验室中,FPN有效抑制了AKT/mTOR和AKT/Jun介导的炎症信号通路.
- FPN在减轻斑马鱼中SDS诱导的炎症方面表现出有效性,在发酵油阶段观察到增强的活性.
结论:
- 这项研究阐明了发酵的Plumula Nelumbinis类化合物的潜在抗皮炎机制.
- 微生物发酵,特别是Aspergillus oryzae,可以增强Plumula Nelumbinis的抗炎活性.
- 这些发现为开发由FPN衍生的新型AD疗法提供了科学基础.
相关概念视频
The JAK-STAT Signaling Pathway
8.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.6K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K

